Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Interferon a-2b + Ribavirin Duration in HIV/HCV Coinfection
NCT00215891Phase 3Completed
- Sponsor
- Hepatitis Resource Network
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C (HCV) (2 arms), sponsored by Hepatitis Resource Network. Primary endpoint: Sustained Virologic Response. Status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00215891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215891.